325 Recruiting Multiple Myeloma Clinical Trials
Explore open interventional and observational research studies actively enrolling participants across the USA. Verify eligibility and contact site coordinators directly.
📍 Find Near Me by DistanceBrowse by State
Browse by Study Phase
Top Interventions for Multiple Myeloma
Related Conditions
Top Recruiting Multiple Myeloma Studies
Ixazomib + Pomalidomide + Dexamethasone In MM
📍 Dana Farber Cancer Institute — Boston, Massachusetts
View Study & Checklist ➔A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant
📍 Moffitt Cancer Center — Tampa, Florida
View Study & Checklist ➔MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb
📍 Beverly Hills Cancer Center — Beverly Hills, California
View Study & Checklist ➔A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma
📍 Mayo Clinic — Phoenix, Arizona
View Study & Checklist ➔A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma
📍 Hackensack University Medical Center — Hackensack, New Jersey
View Study & Checklist ➔A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM
📍 Cross Cancer Institute — Edmonton, Alberta
View Study & Checklist ➔Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy
📍 University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
View Study & Checklist ➔A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
📍 Local Institution - 0131 — Los Angeles, California
View Study & Checklist ➔Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
📍 University of Alabama at Birmingham - Main /ID# 151405 — Birmingham, Alabama
View Study & Checklist ➔2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy
📍 University of Arkansas for Medical Sciences — Little Rock, Arkansas
View Study & Checklist ➔A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
📍 Banner MD Anderson Cancer Center — Gilbert, Arizona
View Study & Checklist ➔A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
📍 University of Arkansas for Medical Sciences — Little Rock, Arkansas
View Study & Checklist ➔S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration
📍 Anchorage Associates in Radiation Medicine — Anchorage, Alaska
View Study & Checklist ➔P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma
📍 City of Hope — Goodyear, Arizona
View Study & Checklist ➔Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
📍 GSK Investigational Site — Tucson, Arizona
View Study & Checklist ➔A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
📍 Duplicate_University of Arizona Cancer Center - North Campus /ID# 218407 — Tucson, Arizona
View Study & Checklist ➔Study to Assess for Measurable Residual Disease (MRD) in Multiple Myeloma Patients
📍 University Of Chicago Medicine Comprehensive Cancer Center — Chicago, Illinois
View Study & Checklist ➔A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and Granulocyte Colony Stimulating Factor (G-CSF) as Compared to Placebo and G-CSF for the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Subjects With Multiple Myeloma (MM)
📍 UCLA Medical Center — Los Angeles, California
View Study & Checklist ➔A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma
📍 Univ of Colorado Cancer Center /ID# 167331 — Aurora, Colorado
View Study & Checklist ➔Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
📍 Levine Cancer Institute — Charlotte, North Carolina
View Study & Checklist ➔A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab
📍 Weill Cornell Medicine - Multiple Myeloma Center — New York, New York
View Study & Checklist ➔Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
📍 Mayo Clinic — Phoenix, Arizona
View Study & Checklist ➔COMbination Regimens in MM Post AHCT to elimiNate MRD Utilizing IbERdomide
📍 University of Alabama at Birmingham — Birmingham, Alabama
View Study & Checklist ➔A Study of MCARH109 and MCARH125 in People With Multiple Myeloma
📍 Memorial Sloan Kettering Basking Ridge (Limited protocol activities) — Basking Ridge, New Jersey
View Study & Checklist ➔A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
📍 Local Institution - 119 — Denver, Colorado
View Study & Checklist ➔A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma
📍 Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
View Study & Checklist ➔A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
📍 Rocky Mountain Cancer Centers — Aurora, Colorado
View Study & Checklist ➔Telehealth-based Symptom Management for Veterans Treated With Selinexor
📍 Durham VA Medical Center — Durham, North Carolina
View Study & Checklist ➔Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
📍 Emory University — Atlanta, Georgia
View Study & Checklist ➔Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101
📍 University of California Davis — Davis, California
View Study & Checklist ➔Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma
📍 Massachusetts General Hospital — Boston, Massachusetts
View Study & Checklist ➔MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
📍 Memorial Sloan Kettering Basking Ridge (Limited protocol activities) — Basking Ridge, New Jersey
View Study & Checklist ➔A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
📍 UCSF — San Francisco, California
View Study & Checklist ➔A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide
📍 Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) — Basking Ridge, New Jersey
View Study & Checklist ➔Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
📍 Arizona Oncology Associates, PC - HOPE — Tucson, Arizona
View Study & Checklist ➔Psychosocial Mobile Application (THRIVE-M) for Patients With Multiple Myeloma
📍 Massachusetts General Hospital — Boston, Massachusetts
View Study & Checklist ➔A Study of Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab for Patients With Relapsed/Refractory Myeloma With Salvage Autologous Hematopoietic Cell Transplantation
📍 University of Alabama Comprehensive Cancer Center — Birmingham, Alabama
View Study & Checklist ➔Isa-Pom-Dex in Elderly/Frail Subjects With RRMM
📍 Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
View Study & Checklist ➔Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma
📍 Mayo Clinic Arizona /ID# 260799 — Phoenix, Arizona
View Study & Checklist ➔